OR WAIT null SECS
May 30, 2024
Johnson & Johnson will gain NM26, a bispecific antibody targeting atopic dermatitis, via the acquisition of a wholly owned subsidiary of Numab Therapeutics.
May 29, 2024
The partnership will create therapeutic assets and new discovery platforms and potentially reshape drug discovery.
May 25, 2024
In an ASGCT Panel on nucleic acid- and cell-based vaccines in oncology, work on a personalized mRNA vaccine was highlighted.
The partnership aims to provide end-to-end development and manufacturing for biopharmaceutical drug substance and drug product.
May 24, 2024
With the acquisition, Biogen gains felzartamab, HI-Bio's lead investigational mAb candidate being developed for the treatment of a range of immune-mediated diseases.
With this acquisition, Merck KGaA will have the capability to offer integrated services for viral vector manufacturing.
May 23, 2024
The units are being recalled because of incomplete crimp seals and one complaint of a leaking unit.
May 22, 2024
The company is collaborating with the Access to Oncology Medicines Coalition to expand patient access to immuno-oncology therapy Opdivo.
May 20, 2024
The new facility will be the company’s first to offer full manufacturing processing for antibody drug conjugates.
After a review, the agency concluded there was a possible risk of cancer to those exposed to 17-hydroxyprogesterone caproate in the womb.